|Bid||2.9100 x 40700|
|Ask||3.0000 x 4000|
|Day's Range||2.8800 - 3.0700|
|52 Week Range||2.0900 - 13.7100|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 09, 2021 - Aug 13, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.71|
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -36.36% and 19.43%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2021 and highlighted recent corporate milestones. The Company will host a conference call today, Monday, May 10, 2021, at 9:00 a.m. Eastern Time.
NEW YORK, NY / ACCESSWIRE / May 10, 2021 / Akebia Therapeutics, Inc. (NASDAQ:AKBA) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 10, 2021 at 9:00 AM Eastern Time.